BridgeBio Oncology Therapeutics to go public via a merger with Helix Acquisition Corp II in a $949m deal.

BridgeBio Oncology Therapeutics, a biotechnology company, agreed to go public via a merger with Helix Acquisition Corp II, a publicly-traded special purpose acquisition company, in a $949m deal. “This financing and transaction mark a significant milestone for our company. We are profoundly grateful to the patients who participate in our trials, our dedicated BBOT team members, and our investors. We believe this transaction is the optimal path to advance our programs and make a meaningful impact on patients affected by deadly cancers,” Eli Wallace, PhD, BBOT Chief Executive Officer.